FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W858884057> ?p ?o ?g. }

• W858884057 abstract "Abstract Introduction Currently there is no standard for second-line salvage therapy in patients with acute myeloid leukemia (AML) who do not respond to initial induction therapy. The efficacy of current recommended second-line salvage regimens seems to be similar, but the tolerability can vary significantly. Anecdotally, high-dose cytarabine (HiDAC) monotherapy seems to be better tolerated than other recommended combination salvage regimens. Therefore, we conducted a retrospective analysis to evaluate the MSKCC experience with HiDAC monotherapy as compared to combination with other chemotherapeutic agents. Methods We included AML patients ≥ 18 years of age who did not respond to first induction therapy and received HiDAC (group 1; cytarabine 3g/m2 q12h for up to 12 doses) or intermediate- or high-dose cytarabine (1g/m2 or 3g/m2 at various numbers of doses) in combination with other agents (group 2) as second-line salvage, between the years 2003 and 2013. The combination group (group 2) consisted of regimens such as: MEC, CLAG, FLAG-I, and mitoxantrone or idarubicin with HiDAC. We evaluated the overall response rate (ORR), relapse free survival (RFS), and overall survival (OS). Univariate analysis was used to evaluate the potential association between outcomes and the following patient characteristics at the time of diagnosis: peripheral and marrow blast count, white blood cell count (WBC), platelet count, anthracycline agent used in first induction, cytogenetics risk, age, comorbidities (cardiac history, diabetes, hypertension, pulmonary, renal, and hepatic compromise), and AML subtype such as de novo (DN), antecedent (AHD), and treatment-related (t-AML). Results Group 1 (monotherapy) had 30 patients and group 2 (combination) had 77 patients. Patient characteristics were similar between the two groups with the exception of age, anthracycline type (daunorubicin vs idarubicin) used in first induction, and transplant status. Group 1 had more patients younger than 58 years old (median), more daunorubicin use, and more patients who underwent allogeneic stem cell transplantation. The side effects in group 1 were notable for pneumonia, C. diff, and bacteremia. The most notable side effects in group 2 were pneumonia, C. diff, bacteremia, sepsis, and treatment-related deaths. No statistically significant difference was observed in ORR (36.7% vs 33.3%; p = 0.922), RFS (9.3 vs 5.9 months; p = 0.53), and OS (12.9 vs 6.8 months; p = 0.329) between group 1 and group 2 respectively. Univariate screening showed no difference in ORR with respect to patient characteristics in group 1. In group 2, ORRs with regard to AML subtype were 64%, 28%, 8% for DN, AHD, t-AML respectively (p = 0.014), and a higher ORR was observed in patients with WBC ≥ 10 K/mcL (58.3% vs 41.7%; p = 0.051) and patients with good or intermediate cytogenetic risks (64% vs 36%; p = 0.017). For RFS, patients in group 1 with WBC > 10 K/mcL were associated with 3 times higher risk of relapse or death (p = 0.029). For RFS in group 2, patients with AHD and t-AML were associated with higher risk of relapse (HR (95% CI): 1.3 and 3.7 respectively, p = 0.002) compared to DN. For OS, patients in group 1 with WBC > 10 K/mcL were at 2.7 times higher risk of death (p = 0.049), an association which was not present in group 2. For OS, patients in group 2 with t-AML and AHD were at 4.2 times and 1.7 times higher risk of death than DN (p = 0.001) and this difference was not present in group 1. Patients with poor cytogenetic risks or comorbidities of interest did worse in terms of overall RFS (p < 0.001, p = 0.02 respectively) and OS (p < 0.001, p = 0.009 respectively). Outcomes did not seem to be associated with type of anthracycline used in first induction or platelet count at diagnosis. Conclusions Recognizing the limitations of a retrospective study, our analysis showed no difference in ORR, RFS, and OS for HiDAC monotherapy compared to intermediate- or high-dose cytarabine combinations. Our univariate analysis suggests statistically significant differences in ORR, RFS, and OS with regard to AML subtype, WBC at time of diagnosis, comorbidities, and cytogenetics risk. We are subcategorizing the combination group into intermediate-dose and high-dose cytarabine combination and compare them to monotherapy. We are looking at additional molecular genetics information besides NPM1, CEBPA, and FLT3 that could also influence outcomes. Disclosures: No relevant conflicts of interest to declare." @default.
• W858884057 created "2016-06-24" @default.
• W858884057 creator A5000623885 @default.
• W858884057 creator A5001124933 @default.
• W858884057 creator A5003194414 @default.
• W858884057 creator A5018708120 @default.
• W858884057 creator A5023629698 @default.
• W858884057 creator A5025660159 @default.
• W858884057 creator A5044552886 @default.
• W858884057 creator A5045087884 @default.
• W858884057 creator A5077063317 @default.
• W858884057 date "2013-11-15" @default.
• W858884057 modified "2023-10-01" @default.
• W858884057 title "High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy" @default.
• W858884057 doi "https://doi.org/10.1182/blood.v122.21.2695.2695" @default.
• W858884057 hasPublicationYear "2013" @default.
• W858884057 type Work @default.
• W858884057 sameAs 858884057 @default.
• W858884057 citedByCount "1" @default.
• W858884057 countsByYear W8588840572015 @default.
• W858884057 crossrefType "journal-article" @default.
• W858884057 hasAuthorship W858884057A5000623885 @default.
• W858884057 hasAuthorship W858884057A5001124933 @default.
• W858884057 hasAuthorship W858884057A5003194414 @default.
• W858884057 hasAuthorship W858884057A5018708120 @default.
• W858884057 hasAuthorship W858884057A5023629698 @default.
• W858884057 hasAuthorship W858884057A5025660159 @default.
• W858884057 hasAuthorship W858884057A5044552886 @default.
• W858884057 hasAuthorship W858884057A5045087884 @default.
• W858884057 hasAuthorship W858884057A5077063317 @default.
• W858884057 hasConcept C126322002 @default.
• W858884057 hasConcept C141071460 @default.
• W858884057 hasConcept C143998085 @default.
• W858884057 hasConcept C197934379 @default.
• W858884057 hasConcept C2776694085 @default.
• W858884057 hasConcept C2776755627 @default.
• W858884057 hasConcept C2776999253 @default.
• W858884057 hasConcept C2778041864 @default.
• W858884057 hasConcept C2778375690 @default.
• W858884057 hasConcept C2778729363 @default.
• W858884057 hasConcept C2779117419 @default.
• W858884057 hasConcept C2779263901 @default.
• W858884057 hasConcept C2780775027 @default.
• W858884057 hasConcept C71924100 @default.
• W858884057 hasConcept C90924648 @default.
• W858884057 hasConceptScore W858884057C126322002 @default.
• W858884057 hasConceptScore W858884057C141071460 @default.
• W858884057 hasConceptScore W858884057C143998085 @default.
• W858884057 hasConceptScore W858884057C197934379 @default.
• W858884057 hasConceptScore W858884057C2776694085 @default.
• W858884057 hasConceptScore W858884057C2776755627 @default.
• W858884057 hasConceptScore W858884057C2776999253 @default.
• W858884057 hasConceptScore W858884057C2778041864 @default.
• W858884057 hasConceptScore W858884057C2778375690 @default.
• W858884057 hasConceptScore W858884057C2778729363 @default.
• W858884057 hasConceptScore W858884057C2779117419 @default.
• W858884057 hasConceptScore W858884057C2779263901 @default.
• W858884057 hasConceptScore W858884057C2780775027 @default.
• W858884057 hasConceptScore W858884057C71924100 @default.
• W858884057 hasConceptScore W858884057C90924648 @default.
• W858884057 hasLocation W8588840571 @default.
• W858884057 hasOpenAccess W858884057 @default.
• W858884057 hasPrimaryLocation W8588840571 @default.
• W858884057 hasRelatedWork W1940598690 @default.
• W858884057 hasRelatedWork W2269151208 @default.
• W858884057 hasRelatedWork W2284340608 @default.
• W858884057 hasRelatedWork W2349850789 @default.
• W858884057 hasRelatedWork W2431621263 @default.
• W858884057 hasRelatedWork W2529976270 @default.
• W858884057 hasRelatedWork W2541409201 @default.
• W858884057 hasRelatedWork W2564574780 @default.
• W858884057 hasRelatedWork W2575273748 @default.
• W858884057 hasRelatedWork W2589011397 @default.
• W858884057 hasRelatedWork W2589245576 @default.
• W858884057 hasRelatedWork W2594234261 @default.
• W858884057 hasRelatedWork W2595261433 @default.
• W858884057 hasRelatedWork W2597342100 @default.
• W858884057 hasRelatedWork W2609558812 @default.
• W858884057 hasRelatedWork W2972355610 @default.
• W858884057 hasRelatedWork W2980271954 @default.
• W858884057 hasRelatedWork W3012638308 @default.
• W858884057 hasRelatedWork W3121824388 @default.
• W858884057 hasRelatedWork W3197318018 @default.
• W858884057 isParatext "false" @default.
• W858884057 isRetracted "false" @default.
• W858884057 magId "858884057" @default.
• W858884057 workType "article" @default.